We’re pleased to announce that updated data from our Phase 2 trial of SNT-5505 in #myelofibrosis will be presented at the European Hematology Association (EHA) 2025 Congress in Milan.
Our abstract, “A Phase 1/2A Trial of PXS-5505, a Novel Pan-Lysyl Oxidase Inhibitor, in Patients with Advanced Myelofibrosis,” will be presented during Poster Session 2 on Saturday, 14 June 2025 (CEST).
This follows strong early data presented at ASH2024 and marks an important milestone as we continue advancing SNT-5505 for patients with myelofibrosis.
View the full $SNT #ASX Announcement here: https://t.co/iTrTMI8Mv9
#Syntara #SNT #EHA2025 #Myelofibrosis #ClinicalTrials #Biotech